Literature DB >> 34850193

Optimizing an effective combination of the new microtubule-targeting agent lisavanbulin with standard-of-care therapy for glioblastoma in patient-derived xenograft preclinical models.

Alain Charest1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34850193      PMCID： PMC8917392          DOI： 10.1093/neuonc/noab278

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.

Authors:  Rachael A Vaubel; Shulan Tian; Dioval Remonde; Mark A Schroeder; Ann C Mladek; Gaspar J Kitange; Alissa Caron; Thomas M Kollmeyer; Rebecca Grove; Sen Peng; Brett L Carlson; Daniel J Ma; Gobinda Sarkar; Lisa Evers; Paul A Decker; Huihuang Yan; Harshil D Dhruv; Michael E Berens; Qianghu Wang; Bianca M Marin; Eric W Klee; Andrea Califano; Daniel H LaChance; Jeanette E Eckel-Passow; Roel G Verhaak; Erik P Sulman; Terry C Burns; Fredrick B Meyer; Brian P O'Neill; Nhan L Tran; Caterina Giannini; Robert B Jenkins; Ian F Parney; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2019-12-18       Impact factor: 12.531

Review 2.  Microtubule-targeting agents and their impact on cancer treatment.

Authors:  Vladimír Čermák; Vojtěch Dostál; Michael Jelínek; Lenka Libusová; Jan Kovář; Daniel Rösel; Jan Brábek
Journal:  Eur J Cell Biol       Date:  2020-05-01       Impact factor: 4.492

3.  A co-clinical platform to accelerate cancer treatment optimization.

Authors:  Andrea Lunardi; Pier Paolo Pandolfi
Journal:  Trends Mol Med       Date:  2014-11-17       Impact factor: 11.951

4.  The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.

Authors:  Ashish Sharma; Angela Broggini-Tenzer; Van Vuong; Alessandra Messikommer; Katarzyna J Nytko; Matthias Guckenberger; Felix Bachmann; Heidi A Lane; Martin Pruschy
Journal:  Radiother Oncol       Date:  2017-08-07       Impact factor: 6.901

5.  A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.

Authors:  Markus Joerger; Anastasios Stathis; Yannis Metaxas; Dagmar Hess; Mara Mantiero; Michael Mark; Matthias Volden; Thomas Kaindl; Marc Engelhardt; Patrice Larger; Heidi Lane; Peter Hafner; Nicole Levy; Silvia Stuedeli; Cristiana Sessa; Roger von Moos
Journal:  Invest New Drugs       Date:  2019-08-30       Impact factor: 3.651

6.  EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.

Authors:  Raphaël Bergès; Aurélie Tchoghandjian; Arnauld Sergé; Stéphane Honoré; Dominique Figarella-Branger; Felix Bachmann; Heidi A Lane; Diane Braguer
Journal:  Oncotarget       Date:  2020-02-25

7.  The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.

Authors:  Raphaël Bergès; Aurélie Tchoghandjian; Stéphane Honoré; Marie-Anne Estève; Dominique Figarella-Branger; Felix Bachmann; Heidi A Lane; Diane Braguer
Journal:  Mol Cancer Ther       Date:  2016-08-18       Impact factor: 6.009

8.  Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.

Authors:  Danielle M Burgenske; Surabhi Talele; Jenny L Pokorny; Ann C Mladek; Katrina K Bakken; Brett L Carlson; Mark A Schroeder; Lihong He; Zeng Hu; Gautham Gampa; Matthew L Kosel; Paul A Decker; Gaspar J Kitange; Anne Schmitt-Hoffmann; Felix Bachmann; Rachael A Vaubel; Jeanette E Eckel-Passow; Caterina Giannini; Paul McSheehy; Heidi A Lane; William F Elmquist; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 13.029

9.  The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.

Authors:  Andrea E Prota; Franck Danel; Felix Bachmann; Katja Bargsten; Rubén M Buey; Jens Pohlmann; Stefan Reinelt; Heidi Lane; Michel O Steinmetz
Journal:  J Mol Biol       Date:  2014-02-11       Impact factor: 6.151

10.  Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.

Authors:  Rebecca Kristeleit; Jeffry Evans; L Rhoda Molife; Nina Tunariu; Heather Shaw; Sarah Slater; Noor R Md Haris; Nicholas F Brown; Martin D Forster; Nikolaos Diamantis; Robert Rulach; Alastair Greystoke; Uzma Asghar; Mihaela Rata; Stephanie Anderson; Felix Bachmann; Alison Hannah; Thomas Kaindl; Heidi A Lane; Patrice J Larger; Anne Schmitt-Hoffmann; Marc Engelhardt; Alexandar Tzankov; Ruth Plummer; Juanita Lopez
Journal:  Br J Cancer       Date:  2020-08-03       Impact factor: 9.075
  10 in total
  1 in total

Review 1.  Updates in IDH-Wildtype Glioblastoma.

Authors:  Mary Jane Lim-Fat; James R Perry; Jawad M Melhem; Jay Detsky
Journal:  Neurotherapeutics       Date:  2022-05-31       Impact factor: 6.088
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.